S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
AI is on the world's mind. Is the UN the place to figure out what to do about it?
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
AI is on the world's mind. Is the UN the place to figure out what to do about it?
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
AI is on the world's mind. Is the UN the place to figure out what to do about it?
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
AI is on the world's mind. Is the UN the place to figure out what to do about it?
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Competitors

$8.35
+0.08 (+0.97%)
(As of 09/22/2023 08:51 PM ET)
Compare
Today's Range
$8.17
▼
$8.44
50-Day Range
$8.27
▼
$12.27
52-Week Range
$4.07
▼
$12.43
Volume
2.04 million shs
Average Volume
2.76 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

AUPH vs. KNSA, SAGE, DAWN, BHVN, ANIP, RVNC, MRUS, ETNB, MIRM, and SNDX

Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Sage Therapeutics (SAGE), Day One Biopharmaceuticals (DAWN), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Revance Therapeutics (RVNC), Merus (MRUS), 89bio (ETNB), Mirum Pharmaceuticals (MIRM), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry.

Aurinia Pharmaceuticals vs.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.

Kiniksa Pharmaceuticals has a net margin of 82.35% compared to Kiniksa Pharmaceuticals' net margin of -45.42%. Aurinia Pharmaceuticals' return on equity of 9.53% beat Kiniksa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals82.35% 9.53% 8.16%
Aurinia Pharmaceuticals -45.42%-18.05%-14.85%

In the previous week, Aurinia Pharmaceuticals had 7 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 1 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 1.04 beat Aurinia Pharmaceuticals' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiniksa Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurinia Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kiniksa Pharmaceuticals has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa Pharmaceuticals$220.18M5.30$183.36M$3.275.09
Aurinia Pharmaceuticals$134.03M8.93-$108.18M-$0.50-16.70

Kiniksa Pharmaceuticals has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

47.3% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.6% of Aurinia Pharmaceuticals shares are owned by institutional investors. 54.2% of Kiniksa Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals currently has a consensus price target of $20.00, suggesting a potential upside of 20.19%. Aurinia Pharmaceuticals has a consensus price target of $13.33, suggesting a potential upside of 59.68%. Given Kiniksa Pharmaceuticals' higher probable upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aurinia Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Aurinia Pharmaceuticals received 404 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 73.08% of users gave Aurinia Pharmaceuticals an outperform vote while only 63.71% of users gave Kiniksa Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Kiniksa PharmaceuticalsOutperform Votes
158
63.71%
Underperform Votes
90
36.29%
Aurinia PharmaceuticalsOutperform Votes
562
73.08%
Underperform Votes
207
26.92%

Summary

Kiniksa Pharmaceuticals beats Aurinia Pharmaceuticals on 10 of the 18 factors compared between the two stocks.


Get Aurinia Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AUPH vs. The Competition

Export to Excel
MetricAurinia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.20B$5.71B$4.33B$6.25B
Dividend YieldN/A2.65%5.81%6.53%
P/E Ratio-16.707.07139.1313.64
Price / Sales8.93151.392,911.6854.71
Price / CashN/A21.5690.04101.36
Price / Book2.934.003.834.78
Net Income-$108.18M$197.48M$121.88M$185.28M
7 Day Performance-0.60%-0.98%110.49%3.51%
1 Month Performance-8.84%-4.38%113.69%8.58%
1 Year Performance18.78%5.24%129.92%4.85%

Aurinia Pharmaceuticals Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KNSA
Kiniksa Pharmaceuticals
1.9043 of 5 stars		$17.54
+1.2%		$20.00
+14.0%		+52.2%$1.23B$220.18M5.36220Positive News
SAGE
Sage Therapeutics
2.466 of 5 stars		$20.45
+0.7%		$43.57
+113.1%		-49.2%$1.22B$7.69M-2.06689
DAWN
Day One Biopharmaceuticals
1.5978 of 5 stars		$14.06
+0.1%		$42.14
+199.7%		-26.8%$1.22BN/A-6.14124
BHVN
Biohaven
2.3625 of 5 stars		$18.07
-1.1%		$25.25
+39.7%		-88.8%$1.23B$462.51M-2.44928
ANIP
ANI Pharmaceuticals
2.5477 of 5 stars		$61.08
-0.6%		$71.67
+17.3%		+84.5%$1.24B$316.39M-127.25600
RVNC
Revance Therapeutics
2.3652 of 5 stars		$13.81
-17.3%		$35.00
+153.4%		-48.0%$1.21B$132.57M-3.05534Analyst Revision
High Trading Volume
MRUS
Merus
1.8241 of 5 stars		$24.98
+0.4%		$44.33
+77.5%		+28.2%$1.25B$41.59M-6.47164
ETNB
89bio
1.9285 of 5 stars		$16.71
-1.9%		$37.44
+124.1%		+222.0%$1.26BN/A-7.9245Analyst Report
Positive News
MIRM
Mirum Pharmaceuticals
2.3063 of 5 stars		$31.00
-3.5%		$50.00
+61.3%		+37.1%$1.19B$77.06M-6.53213
SNDX
Syndax Pharmaceuticals
2.5115 of 5 stars		$17.07
+0.1%		$36.00
+110.9%		-30.4%$1.19B$139.71M-7.02107Options Volume

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:AUPH) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -